Johnson & Johnson Family of Companies
NEWS
There were a fair number of clinical trial announcements last week. Here’s a look.
Johnson & Johnson announced failed Imbokodo Phase IIb trial in HIV. The study evaluated the company’s investigational HIV vaccine regimen in young women in sub-Saharan Africa.
An alleged plan by Johnson & Johnson to spin off a company solely responsible for its talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
The passing of the baton was announced late Thursday. Duato will take over as CEO on Jan. 3, 2022.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
A J&J spokesperson said yesterday that it is collecting more data on whether a booster shot is necessary.
As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of the Moderna and Pfizer-BioNTech vaccines, and probably the Johnson & Johnson vaccine as well.
Visus Therapeutics has acquired an additional $20 million in funding to support its mission of developing innovative ophthalmic therapies for people worldwide.
JOBS
IN THE PRESS
